FPRX

Five Prime Therapeutics Inc

$14.79

+0.98 (+7.10%)

quotes and stock data delayed 15 minutes

52 wk hi

52 wk low

1.86

22.43

Cash

$111.4M

Burn Rate (Qtr)

$26.4M

Mkt Cap

$562.6m

Avg Volume

1,157,443

*cash/burn updated:

Q3'20

Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative protein therapeutics to improve the lives of patients with serious diseases. Five Prime’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. The company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Bemarituzumab (FPA144)

Gastric/ Gastroesophageal Junction (GEJ) tumors

Phase 3

TBA

Initiation

2021 priorities for the bemarituzumab program include collaborating with regulatory agencies on next steps, initiating a global Phase 3 trial in gastric and GEJ cancers and evaluating bemarituzumab in other epithelial cancers that overexpress FGFR2b

FPT155 (CD80-FC)

Advanced solid tumors

Phase 1a

TBA

Data readout

FPA150 (B7-H4)

Breast / Ovarian / Endometrial Cancers

Phase 1b Data

TBA